论文部分内容阅读
目的研究双歧杆菌三联活菌联合标准三联疗法在根除幽门螺杆菌(Helicobacter pylori,Hp)中的治疗效果。方法 Hp感染阳性患者180例,随机分成A、B、C组,每组60例,A、B为对照组,C组为实验组。A组为标准三联方法:奥美拉唑+阿莫西林+克拉霉素;B组用药方案为标准三联+枸橼酸铋钾胶囊;C组用药方案为标准三联+双歧杆菌三联活菌,疗程均为14 d。用药期间记录病人的不适症状,停药4周后复查Hp,阴性为根除;根据3组病人主诉了解治疗过程的不良反应。结果 A、B、C组Hp的根治率分别为70.0%、78.3%和91.7%,A、B组分别与C组比较差异有统计学意义;A、B、C组不良反应发生率分别为18.3%、16.7%和5.0%,A、B组和C组比较差异有统计学意义。结论标准三联+双歧杆菌三联活菌治疗幽门螺杆菌效果好,不良反应少,值得推广。
Objective To study the therapeutic effect of triple live Bifidobacterium combined with standard triple therapy in the eradication of Helicobacter pylori (Hp). Methods 180 patients with positive Hp infection were randomly divided into A, B and C groups, 60 cases in each group. A and B were the control group and the C group was the experimental group. A group for the standard triple method: omeprazole + amoxicillin + clarithromycin; B program for the standard triple + bismuth potassium citrate capsules; C group drug program for the standard triple + Bifidobacterium triple viable bacteria, The course of treatment was 14 days. Record the patient’s symptoms during treatment, Hp withdrawal 4 weeks after the review, negative for eradication; based on the 3 groups of patients complained about the adverse reactions of the treatment process. Results The cure rates of Hp in groups A, B and C were 70.0%, 78.3% and 91.7%, respectively. There was significant difference between group A and B and group C respectively. The incidences of adverse reactions in groups A, B and C were 18.3 %, 16.7% and 5.0% respectively. There was significant difference between A, B and C groups. Conclusion Standard triple + Bifidobacterium triple viable bacteria treatment of Helicobacter pylori good effect, fewer adverse reactions, it is worth promoting.